|
Hemato-oncology
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2021;36(4):975-984. Published online April 6, 2021
Background/Aims: Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer.
Methods: This study included patients with non-small cell..
|
|
|
2020 Korean guidelines for the management of metastatic prostate cancer
In-Ho Kim, Sang Joon Shin, Byung Woog Kang, Jihoon Kang, Dalyong Kim, Miso Kim, Jin Young Kim, Chan Kyu Kim, Hee-Jun Kim, Chi Hoon Maeng, Kwonoh Park, Inkeun Park, Woo Kyun Bae, Byeong Seok Sohn, Min-Young Lee, Jae Lyun Lee, Junglim Lee, Seung Taek Lim, Joo Han Lim, Hyun Chang, Joo Young Jung, Yoon Ji Choi, Young Seok Kim, Jaeho Cho, Jae Young Joung, Se Hoon Park, Hyo Jin Lee
Korean J Intern Med. 2021;36(3):491-514. Published online February 10, 2021
In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in th..
|
|
|
Hemato-oncology
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
Chan-Young Ock, Shin-Hye Yoo, Bhumsuk Keam, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2019;34(5):1116-1124. Published online June 29, 2018
Background/Aims: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factor..
|
|
|
Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
Koung Jin Suh, Ki Hwan Kim, Ryul Kim, Ja Min Byun, Miso Kim, Jin Hyun Park, Bhumsuk Keam, Tae Min Kim, Jin-Soo Kim, In Sil Choi, Dae Seog Heo
Korean J Intern Med. 2019;34(4):894-901. Published online February 23, 2018
Background/Aims: The role of [18F]-f luorodeoxyglucose positron emission tomography-computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) in first remission is unclear.
Methods: Medical costs within the first 3 years of treatment completion and clinical outcomes of 118..
|
|
|
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Korean J Intern Med. 2019;34(4):885-893. Published online November 20, 2017
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy.
Methods..
|
|
|
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med. 2017;32(4):722-730. Published online June 26, 2017
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population.
Methods: We reviewed the medical records of MM patients whose age was 40 ..
|
|
|
